| 臺大學術典藏 |
2020-03-06T05:26:03Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; Liao W.-Y.; Lee J.-H.; Tsai T.-H.; Su K.-Y.; Hsieh M.-S.; YIH-LEONG CHANG; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H. |
| 臺大學術典藏 |
2020-03-06T05:26:00Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; YIH-LEONG CHANG; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-03-05T08:04:11Z |
Clinical and the prognostic characteristics of lung adenocarcinoma patients with ros1 fusion in comparison with other driver mutations in east asian populations
|
Chen Y.-F.; MIN-SHU HSIEH; Wu S.-G.; Chang Y.-L.; Shih J.-Y.; Liu Y.-N.; Tsai M.-F.; Tsai T.-H.; Yu C.-J.; Yang J.C.-H.; Yang P.-C. |
| 臺大學術典藏 |
2020-03-05T08:04:09Z |
Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion
|
Tsai T.-H.; Wu S.-G.; MIN-SHU HSIEH; Yu C.-J.; Yang J.C.H.; Shih J.-Y. |
| 臺大學術典藏 |
2020-03-05T08:04:08Z |
Efficacy of pemetrexed-based chemotherapy in patients with ROS1 fusion-positive lung adenocarcinoma compared with in patients harboring other driver mutations in East Asian populations
|
Chen Y.-F.; MIN-SHU HSIEH; Wu S.-G.; Chang Y.-L.; Yu C.-J.; Yang J.C.-H.; Yang P.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2020-03-05T08:04:01Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; Liao W.-Y.; Lee J.-H.; Tsai T.-H.; Su K.-Y.; MIN-SHU HSIEH; Chang Y.-L.; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H.; Lin C.-C.;Shih J.-Y.;Yu C.-J.;Ho C.-C.;Liao W.-Y.;Lee J.-H.;Tsai T.-H.;Su K.-Y.;Min-Shu Hsieh;Chang Y.-L.;Bai Y.-Y.;Huang D.D.-R.;Thress K.S.;Yang J.C.-H. |
| 臺大學術典藏 |
2020-02-20T02:57:03Z |
Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopy
|
Yu C.-J.; Yang J.C.H.; Yang P.-C.; Shih J.-Y.; Ruan S.-Y.; Wang J.-Y.; Chen K.-Y.; Jan I.-S.; Tsai T.-H.; CHING-YAO YANG; Ho C.-C.; Liao W.-Y. |
| 臺大學術典藏 |
2020-02-06T05:21:56Z |
The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia
|
Lai M.-S.;Yang J.C.H.;Cheng A.-L.;WEN-FANG CHENG;Hsu C.;Shao Y.-Y.;Yang Y.-Y.;Lai C.-L.;Shau W.-Y.;Kuo R.;Lin Z.-Z.;Kuo H.-Y.; Kuo H.-Y.; Lin Z.-Z.; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; Shao Y.-Y.; Hsu C.; WEN-FANG CHENG; Cheng A.-L.; Yang J.C.H.; Lai M.-S.; Kuo H.-Y.; Lin Z.-Z.; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; Shao Y.-Y.; Hsu C.; WEN-FANG CHENG; Cheng A.-L.; Yang J.C.H.; Lai M.-S. |
| 臺大學術典藏 |
2020 |
Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer
|
Kuo S.-H.; Cheng A.-L; Yang J.C.-H; Lu S.-H; Lin Z.-Z; Yu C.-J; Yang W.-C; Feng-Ming Hsu; Chen Y.-H; Shih J.-Y |
| 臺大學術典藏 |
2020 |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.;Wei-Yu Liao;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Liu Y.-N.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Liao B.-C.;Hsu C.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; WEI-YU LIAO; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020 |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yu C.-J.; Yang C.-Y.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tzu-Hsiu Tsai;Hsu C.-L.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Hsu C.-C.;Liao B.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; TZU-HSIU TSAI; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H. |
| 臺大學術典藏 |
2020 |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Su K.-Y.; Chang Y.-L.; Liu Y.-N.; Hsu C.-L.; TZU-HSIU TSAI; Chen K.-Y.; Ho C.-C.; Liao W.-Y.; Yang C.-Y.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020 |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Liao W.-Y.; CHAO-CHI HO; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Yang C.-Y.; Yu C.-J.; Yang J.C.-H.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2020 |
Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer
|
Yang W.-C.;Hsu F.-M.;Chen Y.-H.;Shih J.-Y.;Chong-Jen Yu;Lin Z.-Z.;Lu S.-H.;Yang J.C.-H.;Cheng A.-L.;Kuo S.-H.; Yang W.-C.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; CHONG-JEN YU; Lin Z.-Z.; Lu S.-H.; Yang J.C.-H.; Cheng A.-L.; Kuo S.-H. |
| 臺大學術典藏 |
2020 |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Liu Y.-N.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Liao B.-C.;Hsu C.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Chong-Jen Yu; Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; CHONG-JEN YU |
| 臺大學術典藏 |
2020 |
Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer
|
Kuo S.-H.; Cheng A.-L.; Yang J.C.-H.; Lu S.-H.; Lin Z.-Z.; Yu C.-J.; JIN-YUAN SHIH; Chen Y.-H.; Hsu F.-M.; Yang W.-C.; Yang W.-C.;Hsu F.-M.;Chen Y.-H.;Jin-Yuan Shih;Yu C.-J.;Lin Z.-Z.;Lu S.-H.;Yang J.C.-H.;Cheng A.-L.;Kuo S.-H. |
| 臺大學術典藏 |
2020 |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; CHIA-LIN HSU; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 國立成功大學 |
2020 |
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
|
Sequist, L.V.;Han, J.-Y.;Ahn, M.-J.;Cho, B.C.;Yu, H.;Kim, S.-W.;Yang, J.C.-H.;Lee, J.S.;Su, W.-C.;Kowalski, D.;Orlov, S.;Cantarini, M.;Verheijen, R.B.;Mellemgaard, A.;Ottesen, L.;Frewer, P.;Ou, X.;Oxnard, G. |
| 國立成功大學 |
2020 |
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
|
de, Bono J.;Lin, C.-C.;Chen, L.-T.;Corral, J.;Michalarea, V.;Rihawi, K.;Ong, M.;Lee, J.-H.;Hsu, C.-H.;Yang, J.C.-H.;Shiah, H.-S.;Yen, C.-J.;Anthoney, Anthoney A.;Jove, M.;Buschke, S.;Fuertig, R.;Schmid, U.;Goeldner, R.-G.;Strelkowa, N.;Huang, D.C.-L.;Bogenrieder, T.;Twelves, C.;Cheng, A.-L. |
| 國立成功大學 |
2020 |
Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial
|
Yang, J.C.-H.;Camidge, D.R.;Yang, C.-T.;Zhou, J.;Guo, R.;Chiu, Chiu C.-H.;Chang, G.-C.;Shiah, H.-S.;Chen, Y.;Wang, C.-C.;Berz, D.;Su, W.-C.;Yang, N.;Wang, Z.;Fang, J.;Chen, J.;Nikolinakos, P.;Lu, Y.;Pan, H.;Maniam, A.;Bazhenova, L.;Shirai, K.;Jahanzeb, M.;Willis, M.;Masood, N.;Chowhan, N.;Hsia, T.-C.;Jian, H.;Lu, S. |
| 臺大學術典藏 |
2019 |
Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors
|
Yang J.C.-H.; Tsai T.-H.; Chen K.-Y.; Yu C.-J.; Shih J.-Y.; WEI-YU LIAO; Lee J.-H.;Chen H.-Y.;Hsu F.-M.;Chen J.-S.;Wei-Yu Liao;Shih J.-Y.;Yu C.-J.;Chen K.-Y.;Tsai T.-H.;Yang J.C.-H.; Lee J.-H.; Chen H.-Y.; Hsu F.-M.; Chen J.-S. |
| 臺大學術典藏 |
2019 |
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients
|
Yao Z.-H.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; JIN-YUAN SHIH; Yao Z.-H.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Jin-Yuan Shih;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.-H.;Yu C.-J.; Yu C.-J.; Yang J.C.-H.; Lin C.-C.; Chen J.-S.; Lin Z.-Z. |
| 臺大學術典藏 |
2019 |
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients
|
Yu C.-J.; Yang J.C.-H.; Chen J.-S.; Lin Z.-Z.; Lin C.-C.; Shih J.-Y.; Chen K.-Y.; Ho C.-C.; WEI-YU LIAO; Yao Z.-H.; Yao Z.-H.;Wei-Yu Liao;Ho C.-C.;Chen K.-Y.;Shih J.-Y.;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.-H.;Yu C.-J. |
| 臺大學術典藏 |
2019 |
Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors
|
Yang J.C.-H.; Tsai T.-H.; Chen K.-Y.; Lee J.-H.; Chen H.-Y.; Hsu F.-M.; Chen J.-S.; Liao W.-Y.; Shih J.-Y.; CHONG-JEN YU; Lee J.-H.;Chen H.-Y.;Hsu F.-M.;Chen J.-S.;Liao W.-Y.;Shih J.-Y.;Chong-Jen Yu;Chen K.-Y.;Tsai T.-H.;Yang J.C.-H. |
| 臺大學術典藏 |
2019 |
Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors
|
Yang J.C.-H.; Tsai T.-H.; Chen K.-Y.; Yu C.-J.; Lee J.-H.; Chen H.-Y.; Hsu F.-M.; Chen J.-S.; Liao W.-Y.; JIN-YUAN SHIH; Lee J.-H.;Chen H.-Y.;Hsu F.-M.;Chen J.-S.;Liao W.-Y.;Jin-Yuan Shih;Yu C.-J.;Chen K.-Y.;Tsai T.-H.;Yang J.C.-H. |
